Human Binding Domains Reduce Neurotoxicity of Anti-CD19 CAR-T Cells
Cancer Discovery
|February 2, 2020
Abstract:
Anti-CD19 CAR-T cells with human binding domains were safer in B-cell lymphoma in a phase I trial.
More Related Videos
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.9K
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.7K
